Pharvaris N.V. (PHVS)
NASDAQ:PHVS
PHVS Stock Chart & Stats
$27.35
-$0.46(-2.39%)
At close: 4:00 PM EST
$27.35
-$0.46(-2.39%)
Day’s Range― - ―
52-Week Range$11.51 - $29.80
Previous CloseN/A
Volume14.65K
Average Volume (3M)132.21K
Market Cap
$1.75B
Enterprise Value$1.21B
Total Cash (Recent Filing)$329.29M
Total Debt (Recent Filing)$578.66K
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Apr 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding64,055,640
10 Day Avg. Volume154,872
30 Day Avg. Volume132,211
Financial Highlights & Ratios
PEG Ratio1.31
Price to Book (P/B)3.73
Price to Sales (P/S)0.00
P/FCF Ratio-8.29
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.52K
Enterprise Value/Ebitda-7.83
Forecast
1Y Price Target
$45.63Price Target Upside66.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.68
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyLate-stage on-demand study showed rapid, injectable-like symptom relief and durable benefits that support the drug's effectiveness for immediate treatment of acute attacks.
Formulation ConvenienceExtended-release oral formulation sustains therapeutic levels for a full day, enabling single-capsule once-daily dosing that could improve adherence versus injectables.
Label And Commercial DifferentiationManagement's label strategy focusing on rapid symptom relief, progression to complete resolution, and one-capsule control could create a differentiated commercial narrative for clinicians and patients.
Bears Say
Rare-indication Enrollment RiskEnrollment and outcomes in an ultra-rare acquired angioedema study are uncertain, and operational challenges in rare-disease trials could limit the incremental value from that indication.
Regulatory Submission RiskKey regulatory submissions and additional pivotal data readouts remain required, creating execution risk that could delay approval and commercialization plans.
Research Provider Conflict RiskThe research provider's potential business relationships with covered companies may create conflicts of interest that could undermine the perceived objectivity of analyses.
Pharvaris News
PHVS FAQ
What was Pharvaris N.V.’s price range in the past 12 months?
Pharvaris N.V. lowest stock price was $11.51 and its highest was $29.80 in the past 12 months.
What is Pharvaris N.V.’s market cap?
Pharvaris N.V.’s market cap is $1.75B.
When is Pharvaris N.V.’s upcoming earnings report date?
Pharvaris N.V.’s upcoming earnings report date is Apr 14, 2026 which is in 16 days.
How were Pharvaris N.V.’s earnings last quarter?
Pharvaris N.V. released its earnings results on Nov 12, 2025. The company reported -$0.693 earnings per share for the quarter, beating the consensus estimate of -$0.77 by $0.077.
Is Pharvaris N.V. overvalued?
According to Wall Street analysts Pharvaris N.V.’s price is currently Undervalued.
Does Pharvaris N.V. pay dividends?
Pharvaris N.V. does not currently pay dividends.
What is Pharvaris N.V.’s EPS estimate?
Pharvaris N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharvaris N.V. have?
Pharvaris N.V. has 64,055,640 shares outstanding.
What happened to Pharvaris N.V.’s price movement after its last earnings report?
Pharvaris N.V. reported an EPS of -$0.693 in its last earnings report, beating expectations of -$0.77. Following the earnings report the stock price went up 7.007%.
Which hedge fund is a major shareholder of Pharvaris N.V.?
Currently, no hedge funds are holding shares in PHVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharvaris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.63 (66.84% Upside)
$45.63 (66.84% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 583.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.65%
12-Months-Change
Fundamentals
Return on Equity
-67.11%
Trailing 12-Months
Asset Growth
13.93%
Trailing 12-Months
Company Description
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
PHVS Stock 12 Month Forecast
Average Price Target
$45.63
▲(66.84% Upside)
Technical Analysis
Ownership Overview
―
Insiders
8.89% Mutual Funds
62.17% Other Institutional Investors
27.66% Public Companies and
Individual Investors